On the Mark
This article was originally published in Start Up
Executive SummaryAventis and the German state of Hesse teamed up to create a public/private venture fund, in part to salve the political wounds of Hoechst's leaving its Frankfurt headquarters for Strasbourg, France. While any of its investments need to have a Hessen connection, the slowdown in the German VC boom makes this new fund a potentially important source of capital.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.